Brokerages Set Natera, Inc. (NASDAQ:NTRA) Target Price at $182.12

Natera, Inc. (NASDAQ:NTRA - Get Free Report) has received an average recommendation of "Buy" from the sixteen analysts that are covering the stock, MarketBeat reports. Sixteen equities research analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $182.12.

Several equities analysts have recently issued reports on NTRA shares. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $180.00 price objective on shares of Natera in a research note on Wednesday, February 26th. Robert W. Baird lifted their price target on shares of Natera from $183.00 to $188.00 and gave the stock an "outperform" rating in a research report on Friday, February 28th. Piper Sandler raised their price objective on Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a research note on Thursday, May 15th. Morgan Stanley lifted their target price on Natera from $176.00 to $185.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. Finally, Barclays boosted their target price on Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a research report on Friday, May 9th.

Insider Activity at Natera

In related news, insider Solomon Moshkevich sold 2,206 shares of the stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $152.18, for a total value of $335,709.08. Following the transaction, the insider now owns 139,280 shares in the company, valued at approximately $21,195,630.40. This represents a 1.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Steven Leonard Chapman sold 87,272 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $143.40, for a total transaction of $12,514,804.80. Following the transaction, the chief executive officer now directly owns 203,354 shares in the company, valued at approximately $29,160,963.60. The trade was a 30.03% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 152,436 shares of company stock valued at $22,019,079. Corporate insiders own 7.60% of the company's stock.

Institutional Trading of Natera

Large investors have recently added to or reduced their stakes in the business. LRI Investments LLC acquired a new stake in shares of Natera in the 4th quarter valued at $29,000. Bank of Jackson Hole Trust bought a new position in Natera during the first quarter valued at about $29,000. Blue Trust Inc. raised its holdings in Natera by 104.3% during the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock valued at $30,000 after buying an additional 97 shares in the last quarter. Rakuten Securities Inc. lifted its position in shares of Natera by 117.8% in the first quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock worth $31,000 after buying an additional 119 shares during the last quarter. Finally, TCTC Holdings LLC raised its stake in shares of Natera by 114.8% in the 1st quarter. TCTC Holdings LLC now owns 232 shares of the medical research company's stock valued at $33,000 after acquiring an additional 124 shares in the last quarter. 99.90% of the stock is owned by institutional investors.

Natera Price Performance

NTRA traded down $1.93 during trading on Wednesday, reaching $156.12. The stock had a trading volume of 2,767,726 shares, compared to its average volume of 1,404,603. The stock has a 50 day moving average of $149.91 and a two-hundred day moving average of $158.37. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $21.32 billion, a price-to-earnings ratio of -88.70 and a beta of 1.79. Natera has a 1-year low of $92.14 and a 1-year high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.09. The business had revenue of $501.83 million during the quarter, compared to analyst estimates of $446.68 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company's revenue was up 36.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.56) earnings per share. As a group, equities analysts anticipate that Natera will post -1.49 EPS for the current fiscal year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.